Hikma Pharmaceuticals PLC (OTCMKTS:HKMPY – Get Free Report) was the target of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 1,000 shares, a decrease of 50.0% from the February 13th total of 2,000 shares. Based on an average daily trading volume, of 600 shares, the short-interest ratio is presently 1.7 days.
Hikma Pharmaceuticals Price Performance
Shares of OTCMKTS HKMPY traded up $0.39 during mid-day trading on Friday, reaching $52.79. The company’s stock had a trading volume of 2,777 shares, compared to its average volume of 922. The stock has a 50-day moving average of $54.73 and a two-hundred day moving average of $51.65. Hikma Pharmaceuticals has a 1-year low of $46.16 and a 1-year high of $59.26.
Hikma Pharmaceuticals Increases Dividend
The firm also recently announced a dividend, which will be paid on Monday, May 12th. Stockholders of record on Friday, March 21st will be given a $0.94 dividend. This is a boost from Hikma Pharmaceuticals’s previous dividend of $0.62. The ex-dividend date is Friday, March 21st. Hikma Pharmaceuticals’s dividend payout ratio is 10.34%.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Recommended Stories
- Five stocks we like better than Hikma Pharmaceuticals
- How to Capture the Benefits of Dividend Increases
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- 3 Stocks to Consider Buying in October
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- The Role Economic Reports Play in a Successful Investment Strategy
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.